Status:
UNKNOWN
Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy
Lead Sponsor:
Ain Shams University
Conditions:
Breast Cancer Female
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Patients with breast cancer receiving systemic therapy have a variety of symptoms. In cancer patients receiving chemotherapy and targeted therapy, it is common to report symptoms to physicians before...
Detailed Description
In Egypt, breast cancer is the most frequent malignancy among Egyptian women, accounting for 38.8% of cancers in this population, with the expected number of breast cancer cases nearly 22, 700 in 2020...
Eligibility Criteria
Inclusion
- Stage I-III breast cancer under adjuvant intravenous chemotherapy with or without targeted therapy.
- Able to provide a written informed consent .
- Must have an internet access.
Exclusion
- Presence of other malignancies whether in the past or simultaneously.
- Male cancer patients.
- Clinical diagnosis of Alzheimer's disease.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05401942
Start Date
June 1 2022
End Date
May 1 2024
Last Update
June 2 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.